

<https://doi.org/10.1038/s43856-024-00466-2>

Low-calorie diets for people with isolated impaired fasting glucose

Sathish Thirunavukkarasu, Roy Taylor, Kamlesh Khunti, Robyn J. Tapp, Anne Raben, Ruixin Zhu, Nitin Kapoor, K M Venkat Narayan, Mohammed K. Ali & Jonathan E. Shaw

Check for updates

Standard lifestyle interventions prove ineffective in preventing type 2 diabetes among individuals with isolated impaired fasting glucose, a highly prevalent prediabetes phenotype globally. Here, we propose low-calorie diets as a promising strategy for diabetes prevention in this high-risk population.

Prediabetes represents an intermediary stage in the development of type 2 diabetes¹. It is characterized by elevated glucose levels that are higher than normal but below the diabetes diagnostic threshold¹. Prediabetes is not a single condition; rather, it encompasses a diverse range of phenotypes, including isolated impaired fasting glucose (i-IFG), isolated impaired glucose tolerance (i-IGT), and IFG plus IGT^{2,3}.

i-IFG constitutes a significant proportion of the global prediabetes population, ranging from 43.9% to 58.0% among Caucasians and 29.2% to 48.1% among Asian people, depending on the diagnostic criteria⁴. It is characterized by fasting hyperglycemia and normal 2-hour plasma glucose levels after a 75-g glucose load during an oral glucose tolerance test^{5,6}. i-IFG is marked by impaired early-phase insulin secretion and hepatic insulin resistance (liver is less responsive to insulin action), which strongly correlates with liver fat content^{7,8}. Individuals with i-IFG experience an annual diabetes progression rate of 3.6% to 5.2%⁹ and have a four- to six-fold higher risk of developing type 2 diabetes compared to those with normoglycemia, depending on the diagnostic criteria⁹. Additionally, i-IFG carries an elevated risk of vascular complications and all-cause mortality^{3,10}.

In a systematic review by Bodhini et al. published in *Communications Medicine*, the authors investigated the variability in the effectiveness of lifestyle interventions for preventing type 2 diabetes across various socio-demographic, clinical, behavioral, and genetic factors¹¹. Their analysis, based on data from 81 studies (comprising 33 unique clinical trials), demonstrated that individuals with prediabetes tend to benefit more from prevention strategies compared to those without prediabetes¹¹. Consequently, the authors recommend targeting individuals with prediabetes for diabetes prevention programs. Moreover, they emphasize the importance of further research to investigate whether individuals with distinct pathophysiological features might benefit from more tailored preventive interventions. Such efforts could help address the existing gaps in evidence regarding the precision prevention of type 2 diabetes.

While standard lifestyle interventions, such as low-fat, high-fiber diets, and increased aerobic physical activity, are highly effective in reducing diabetes incidence in those with IGT, regardless of the presence of IFG, they have proven ineffective among those with i-IFG¹². These findings stem from a recent individual participant data meta-analysis that pooled data from four randomized controlled trials conducted in India, Japan, and the UK. The analysis included 2794 participants: 1240 (44.4%), 796 (28.5%), and 758

(27.1%) had i-IFG, i-IGT, and IFG plus IGT, respectively. After a median follow-up of 2.5 years, the pooled hazard ratio for diabetes incidence in i-IFG was 0.97 (95% CI: 0.66, 1.44, $I^2 = 0$), i-IGT was 0.65 (95% CI: 0.44, 0.96, $I^2 = 0$), and IFG plus IGT was 0.51 (95% CI: 0.38, 0.68, $I^2 = 0$); $P_{\text{interaction}} = 0.01$ ¹². Standard lifestyle interventions primarily target the pathophysiological defects associated with IGT, notably improving peripheral insulin sensitivity and preserving or enhancing β -cell function^{13–15}. However, they do not effectively address hepatic insulin resistance³, which is the key underlying defect responsible for fasting hyperglycemia in individuals with i-IFG².

In recent years, low-calorie diets ranging from 800–1500 kcal/day have gained significant attention in managing type 2 diabetes^{8,16–19}. Studies have shown that low-calorie diets can lead to remission and substantial improvements in cardiometabolic risk factors for a significant proportion of individuals with type 2 diabetes^{8,16–19}. These diets are generally well-tolerated and safe, with only mild side effects reported. Table 1 summarizes the key low-calorie diet studies conducted in people with type 2 diabetes^{8,16–19}. Studies implementing low-calorie diets over a 2–5 month period, primarily high in protein and low in fat, have resulted in a mean weight loss of 7–15 kg (8–15% of initial body weight). This level of weight loss was accompanied by a notable reduction in hepatic fat and improved hepatic insulin sensitivity and first-phase insulin secretion. As a result, fasting plasma glucose levels decreased significantly by 27.8 to 43.2 mg/dL. This suggests that low-calorie diets may also be effective for individuals with i-IFG, as they target the pathophysiological defects characterizing this prediabetes phenotype^{8,16–19}. Figure 1 visually depicts the potential reversal of the twin cycle hypothesis through low-calorie diets in individuals with i-IFG. The twin cycle hypothesis²⁰ postulates that chronic excess calorie intake results in increased accumulation of fat in the liver, leading to resistance against insulin's suppression of hepatic glucose production. Additionally, excess liver fat increases lipid transportation to the pancreas, impairing β -cell function and further promoting hepatic glucose production. These self-reinforcing cycles between the liver and pancreas ultimately result in the onset of hyperglycemia.

The assertion that low-calorie diets could potentially reverse the twin cycle hypothesis in i-IFG is supported by a post-hoc analysis of the PREVIEW (PREvention of diabetes through lifestyle interventions and population studies In Europe and around the World) study, involving 869 individuals (mean age 55.0 years) with overweight (body mass index ≥ 25 kg/m²) and i-IFG²¹. Following an 8-week low-calorie diet phase (810 kcal/day; 41.2% carbohydrate, 43.7% protein, 15.1% fat), the mean weight loss was 10.8 kg (10.7%), with more than four-fifths (82.7%) of participants achieving the targeted weight loss of $\geq 8\%$. Notably, the weight loss led to a reduction in mean fasting plasma glucose of 6.5 mg/dl, with slightly over one-third (36.1%) achieving normoglycemia based on fasting plasma glucose alone²¹. The hepatic insulin resistance index significantly decreased by 30%, from 76.69 (SD: 2.31) to 47.42 (SD: 2.41), $p < 0.001$.

Table 1 | Summary of key low-calorie diet studies in people with type 2 diabetes

Study	Study design & Setting	Study population	Intervention group	Control group	Outcomes
Petersen et al. ⁹	Pre- and Post-intervention study conducted in Yale Gen-eral Clinical Research Cen-ter, USA	8 patients (mean age: 47 [SD: 3] years) with type 2 diabetes and BMI ≥ 30 kg/m ²	LCD formula (~1200 kcal/day; 50% carbohydrate, 43% protein, 3% fat, 12 g of fiber) for 2 months	None	<ul style="list-style-type: none"> Weight loss: 8.0 kg (8.0% of initial weight), $p < 0.0001$ Liver fat content: 81% reduction from baseline ($p = 0.009$) Hepatic insulin sensitivity: insulin suppression of hepatic glucose output increased from 29% to 93%, $p = 0.04$ Fasting plasma glucose: reduced by 43.2 mg/dl (from 158.4 mg/dl to 115.2 mg/dl), $p < 0.0001$
DIRECT trial, Lean et al. ¹⁶ , Taylor et al. ¹⁹	RCT conducted at 46 primary care centers in Scotland and the Tyneside region of England	298 adults (20–65 years) with type 2 diabetes within 6 years of diagnosis and BMI 27–45 kg/m ²	LCD (825–853 kcal/day; 59% carbo-hydrate, 13% fat, 26% protein, 2% fiber) intervention for 3–5 months	Routine diabetes care	<ul style="list-style-type: none"> In the Tyneside cohort ($n = 58$): Weight loss: 14.8 kg (14.7% of initial weight), $p < 0.0001$ Liver fat percent: reduced by 127%, $p < 0.0001$ Early-phase insulin secretion: increased by 0.04 nmol/min/m², $p < 0.0001$ Fasting plasma glucose: reduced by 27.8 mg/dl, $p < 0.0001$
DIADeM-H trial, Taheri et al. ¹⁸	RCT conducted in primary care and community settings in Qatar	158 adults (aged 18–50 years) with a short duration (≤ 3 years) of type 2 diabetes and BMI ≥ 27.0 kg/m ²	An LCD formula (800–820 kcal/day; 57% carbohydrate, 14% fat, 26% protein, 3% fiber) for 3 months	Usual diabetes care	<ul style="list-style-type: none"> Weight loss: reduced by 12.0 kg (10.3%) in intervention partici-pants and 4.0 kg (4.8%) in control participants (difference: -6.08 kg, 95% CI -8.37, -3.79; $p < 0.0001$) Insulin sensitivity: improved, as measured by the QUICKI index, by 0.016 points in intervention participants and reduced by 0.006 points in control participants (difference: 0.025, 95% CI 0.015, 0.035; $p < 0.001$)
STANDBY trial, Sattar et al. ¹⁷	RCT conducted in primary care practices in the U.K	25 adults (aged 18–65 years) of South Asian ethnicity with type 2 diabetes for ≤ 4 years and BMI 25–45 kg/m ²	An LCD (825–853 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) intervention for 3–5 months	Usual diabetes care	<ul style="list-style-type: none"> Weight loss: reduced by 7.2 kg (7.7%) in the intervention group as compared to 0.9 kg (1.2%) in the control group (difference: -6.3 kg, 95% CI -11.0, -1.6; $p = 0.011$) Fasting plasma glucose: reduced by 18.0 mg/dl in intervention participants and 9.0 mg/dl in control participants (difference: -9.0 mg/dl, 95% CI -34.2, 14.4; $p = 0.41$)

DIRECT Diabetes Remission Clinical Trial, BMI body mass index, RCT randomized controlled trial, LCD low-calorie diet, FPG fasting plasma glucose, SD standard deviation, CI confidence interval, QUICKI quantitative insulin-sensitivity check index.




Fig. 1 | Potential reversal of the twin cycle hypothesis through low-calorie diets in isolated impaired fasting glucose. VLDL very low density lipoprotein.

Current diabetes prevention guidelines fail to recognize the heterogeneity of prediabetes^{22–24} concerning differences in pathophysiological abnormalities^{2,3} and progression rates to type 2 diabetes among its phenotypes⁹. These guidelines inform the design and development of national diabetes prevention programs that typically deliver standard lifestyle interventions to individuals with any prediabetes phenotype^{25–27}. However, recent evidence suggests that standard lifestyle interventions prove ineffective for individuals with i-IFG, while they remain highly effective for those with IGT (with or without IFG) in reducing diabetes incidence^{12,28,29}. Therefore, there is an urgent need for further research to identify lifestyle modification strategies tailored specifically to address the distinct pathophysiological defects associated with i-IFG, including investigating the potential efficacy of low-calorie diets.

Sathish Thirunavukkarasu¹✉, Roy Taylor^{2,9}, Kamlesh Khunti³, Robyn J. Tapp⁴, Anne Raben⁵, Ruixin Zhu⁵, Nitin Kapoor⁶, K M Venkat Narayan⁷, Mohammed K. Ali^{1,9} & Jonathan E. Shaw^{8,9}

¹Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, USA. ²Translational and Clinical Research Institute, Magnetic Resonance Centre, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK. ³Diabetes Research Centre, University of Leicester, Leicester, UK. ⁴Centre for Intelligent Health Care, Coventry University, Coventry, UK. ⁵Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. ⁶Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India. ⁷Emory Global Diabetes Research Center, Woodruff Health Sciences Center, Emory University, Atlanta, GA, USA. ⁸Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. ⁹These authors jointly supervised this work: Roy Taylor, Mohammed K. Ali, Jonathan E. Shaw.

✉e-mail: sathish.thirunavukkarasu@emory.edu

Received: 4 November 2023; Accepted: 22 February 2024;

Published online: 01 March 2024

References

1. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J. & Kivimäki, M. Prediabetes: a high-risk state for diabetes development. *Lancet* **379**, 2279–2290 (2012).
2. Abdul-Ghani, M. A., Tripathy, D. & DeFronzo, R. A. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. *Diabetes Care* **29**, 1130–1139 (2006).
3. Campbell, M. D. et al. Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype. *Nat. Rev. Endocrinol.* **16**, 395–400 (2020).
4. Yip, W. C. Y., Sequeira, I. R., Plank, L. D. & Poppitt, S. D. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. *Nutrients* **9**, 1273 (2017).
5. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2024. *Diabetes Care* **47**, S20–S42 (2024).
6. World Health Organization & International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Available at <https://www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia>.
7. Lim, E. L. et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* **54**, 2506–2514 (2011).
8. Petersen, K. F. et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* **54**, 603–608 (2005).
9. Richter, B., Hemmingsen, B., Metzendorf, M. I. & Takwoingi, Y. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. *Cochrane Database Syst. Rev.* **10**, CD012661 (2018).
10. Huang, Y., Cai, X., Mai, W., Li, M. & Hu, Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. *BMJ* **355**, i5953 (2016).
11. Bodhini, D. et al. Impact of individual and environmental factors on dietary or lifestyle interventions to prevent type 2 diabetes development: a systematic review. *Commun. Med. (Lond)* **3**, 133 (2023).
12. Sathish, T. et al. Effect of conventional lifestyle interventions on type 2 diabetes incidence by glucose-defined prediabetes phenotype: an individual participant data meta-analysis of randomized controlled trials. *Diabetes Care* **46**, 1903–1907 (2023).
13. Kitabchi, A. E. et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. *Diabetes* **54**, 2404–2414 (2005).

14. Uusitupa, M. et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. *Diabetes* **52**, 2532–2538 (2003).
15. Snehalatha, C. et al. Changes in insulin secretion and insulin sensitivity in relation to the glycaemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). *Diabetes Care* **32**, 1796–1801 (2009).
16. Lean, M. E. J. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol.* **7**, 344–355 (2019).
17. Sattar, N. et al. Dietary weight-management for type 2 diabetes remissions in South Asians: the South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDBy). *Lancet Reg Health Southeast Asia* **9**, 100111 (2023).
18. Taheri, S. et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADeM-I): an open-label, parallel-group, randomised controlled trial. *Lancet Diabetes Endocrinol.* **8**, 477–489 (2020).
19. Taylor, R. et al. Remission of human Type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. *Cell Metab.* **28**, 547–556 (2018).
20. Taylor, R. Type 2 diabetes: etiology and reversibility. *Diabetes Care* **36**, 1047–1055 (2013).
21. Zhu, R. et al. Does the effect of a 3-year lifestyle intervention on body weight and cardiometabolic health differ by prediabetes metabolic phenotype? A post hoc analysis of the PREVIEW study. *Diabetes Care* **45**, 2698–2708 (2022).
22. American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. *Diabetes Care* **47**, S43–S51 (2024).
23. Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur. Heart J.* **41**, 255–323 (2020).
24. National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. Available at www.nice.org.uk/guidance/ph38.
25. Saaristo, T. et al. National type 2 diabetes prevention programme in Finland: FIN-D2D. *Int. J. Circumpolar Health* **66**, 101–112 (2007).
26. Ely, E. K. et al. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC's national diabetes prevention program. *Diabetes Care* **40**, 1331–1341 (2017).
27. Valabhji, J. et al. Early outcomes from the English national health service diabetes prevention programme. *Diabetes Care* **43**, 152–160 (2020).
28. Sathish, T., Tapp, R. J. & Shaw, J. E. Do lifestyle interventions reduce diabetes incidence in people with isolated impaired fasting glucose? *Diabetes Obes. Metab.* **23**, 2827–2828 (2021).
29. Chakkalakal, R. J., Galaviz, K. I., Sathish, T., Shah, M. K. & Narayan, K. M. V. Test and treat for prediabetes: a review of the health effects of prediabetes and the role of screening and prevention. *Annu. Rev. Public Health*, <https://doi.org/10.1146/annurev-publhealth-060222-023417> (2023).

Acknowledgements

The research reported in this publication received support from the Woodruff Health Sciences Center Synergy Awards and the Pilot grants program of the Georgia Clinical & Translational Science Alliance (CTSA), funded by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. Additionally, we acknowledge the contribution of Emory's Open Access Publication Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. S.T. and M.K.A. were partially

supported by grant #75D30120P0742 from the Centers for Disease Control and Prevention (CDC) Atlanta. M.K.A. and K.M.V.N. were partially supported by the Georgia Center for Diabetes Translation Research (NIDDK P30DK111024). K.K. was supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and the NIHR Leicester Biomedical Research Centre (BRC). J.E.S. was supported by an Australian National Health and Medical Research Council Investigator grant.

Author contributions

S.T. drafted the manuscript and designed the figure; R.T. critically reviewed the manuscript and supervised the work of S.T.; K.K. critically reviewed the manuscript; R.J.T. critically reviewed the manuscript; A.R. critically reviewed the manuscript; R.Z. critically reviewed the manuscript; N.K. critically reviewed the manuscript; K.M.V.N. critically reviewed the manuscript; M.K.A. critically reviewed the manuscript and supervised the work of S.T.; J.E.S. critically reviewed the manuscript and supervised the work of S.T.

Competing interests

R.T. reports lecture fees from Lilly and Novartis and consultancy fees from Wilmington Healthcare and the Fast800, outside of the submitted work. K.K. was Chair of the National Institute for Health and Care Excellence (NICE) Public Health Guidance (PH38) Type 2 diabetes: Prevention in people at high risk. A.R. has received honoraria from Nestlé, Unilever, and the International Sweeteners Association, outside of the submitted work. M.K.A. reports consulting fees from Eli Lilly, outside of the submitted work. All other authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Sathish Thirunavukkarasu.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024